Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the period ending April 29, 2026. The document reports the results of the Company's 2026 Annual General Meeting (AGM) held on that date. Haleon is a consumer health company focused on everyday health, with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a report of corporate governance voting outcomes and does not contain financial performance data for the period.
Material Changes and Voting Results
All resolutions presented at the AGM were passed. Key voting outcomes include:
- Dividend Approval: Resolution 4 to declare a final dividend was approved with 99.99% of votes cast in favor.
- Board Re-elections: All incumbent directors, including CEO Manvinder Singh (Vindi) Banga, were re-elected with support ranging from 98.99% to 99.96%.
- Remuneration: The Directors' Remuneration Report was approved by 98.00% of votes, while the Remuneration Policy received 94.65% support.
- Shareholder Authority: Resolutions to disapply pre-emption rights (Resolutions 20 and 21) passed with 95.20% and 92.78% support, respectively. Authority to purchase own shares was approved by 99.93%.
- Auditor: KPMG was re-appointed as auditor with 99.98% support.
Total voting rights in the Company were 8,891,124,301, with approximately 84.8% of issued share capital voted.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. It notes that copies of resolutions have been submitted to the UK Financial Conduct Authority (FCA) via the National Storage Mechanism.
Investor Verification Checklist
- Verify the specific amount of the final dividend declared in Resolution 4, as the filing confirms approval but not the monetary value.
- Review the full text of the Directors' Remuneration Report and Policy to understand the compensation structure approved by 98% and 94.65% of shareholders.
- Confirm the scope of the share buyback authority granted in Resolution 23.
- Check the Company's Notice of 2026 AGM for the full text of the special resolutions (20-23) regarding pre-emption rights and meeting notice periods.